Atara Biotherapeutics Provides a Business Update
MWN-AI** Summary
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, has announced a business update regarding its agreement with HealthCare Royalty (HCRx). The recent amendment to their Purchase and Sale Agreement delays a significant milestone payment of $9 million from June 30, 2026, to January 1, 2028. This change is particularly critical as Atara addresses concerns related to a Complete Response Letter (CRL) from the FDA regarding its lead product, tabelecleucel, a treatment aimed at EBV+ PTLD, a rare form of lymphoma.
Cokey Nguyen, Atara’s CEO, expressed gratitude for this extension, emphasizing its importance in focusing on regulatory challenges and collaboration with their partner, Pierre Fabre. The delay in payment provides Atara with additional flexibility to further explore pathways to FDA approval amid significant unmet needs in the treatment landscape.
As part of the amendment, Atara has issued a warrant allowing HCRx to purchase up to 400,000 shares of common stock at a nominal price, a strategic move that ties HCRx's interests to Atara's future performance.
Tabelecleucel is highlighted as a critical option for patients in Europe suffering from this aggressive cancer, reinforcing Atara's mission to harness T-cell technology for innovative cancer treatment. The company prides itself on being the first to gain regulatory approval for an allogeneic T-cell therapy, with a focus on simplifying access to treatment for complex health issues.
Investors should note that Atara is navigating a landscape filled with uncertainties, particularly concerning FDA reviews, capital access, and the broader challenges of drug development. As they work towards securing a viable option for patients, the company's progress will remain closely monitored by stakeholders and market analysts alike.
MWN-AI** Analysis
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) has recently made notable changes regarding its financial commitments and strategic partnerships that could have implications for investors. The renegotiation of the one-time $9 million cash payment due to HealthCare Royalty (HCRx) extends the payment due date from June 2026 to January 2028. This adjustment provides Atara with increased financial flexibility, allowing the company to focus on addressing challenges highlighted in the recent Complete Response Letter (CRL) from the FDA regarding its lead asset, tabelecleucel.
Investors should consider this extension positively, as it indicates that Atara is prioritizing regulatory and developmental hurdles associated with tabelecleucel, which targets the significant unmet needs of patients suffering from relapsed or refractory EBV+ PTLD. Given the lack of effective treatment options available in the market, successful navigation of these regulatory challenges could result in substantial market opportunities.
The issuance of warrants that allow HCRx to purchase up to 400,000 shares at a nominal price reflects a strategic move by Atara to strengthen its collaboration with HCRx while providing another layer of capital-raising potential without immediate dilution. However, investors should remain cautious; the lack of an expiry date on the warrants could lead to increased share dilution if exercised by HCRx.
The focus on advancing tabelecleucel amidst the backdrop of limited treatment alternatives positions Atara favorably in the niche oncology market. Nevertheless, potential investors should be mindful of the risks associated with FDA approvals and funding pathways. Given these factors, a balanced approach—considering both the potential and the uncertainties—would be prudent for those looking to invest in Atara Biotherapeutics.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Atara renegotiates one-time milestone payment with HCRx
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the Company entered into an amendment (the Amendment) to the Purchase and Sale Agreement dated as of December 20, 2022 with a fund managed by HealthCare Royalty (“HCRx”). Under the terms of the Amendment, HCRx agreed to amend the due date of the one-time of $9.0 million cash payment associated with the achievement of a certain milestone within the Amended and Restated Commercialization Agreement dated October 31, 2023, with Pierre Fabre Medicament, as amended, from June 30, 2026 to January 1, 2028.
“We are thankful for this extension to our one-time cash payment to HCRx,“ said Cokey Nguyen, President and Chief Executive Officer of Atara. “This flexibility allows us to focus on addressing the concerns in the latest CRL with the agency, supporting our partners, Pierre Fabre. We believe in the potential of tabelecleucel and are optimistic about the path forward.”
In connection with the Amendment, the Company issued a warrant to purchase up to 400,000 shares of the Company’s Common Stock. The exercise price of the Warrant is equal to $0.0001 per share, subject to adjustment as provided therein, and the Warrants will be exercisable immediately and have no expiration date. The exercise of the Warrant is subject to a beneficial ownership limit as set forth in the Warrant.
“Tabelecleucel is proving to be an important option for European patients suffering from relapsed or refractory EBV+ PTLD, an ultra-rare and aggressive lymphoma,“ said Clarke Futch, Chairman and Chief Executive Officer at HCRx. “This amendment to our agreement provides Atara and their partner time to work with the FDA for a path to approval in the United States, where there remain limited treatment options and significant unmet need.”
About Atara Biotherapeutics, Inc.
Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases. Atara is headquartered in Southern California. For more information, visit atarabio.com and follow @Atarabio on X and LinkedIn .
Forward-Looking Statements
This press release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding: (1) the development, timing, and progress of tab-cel; and (2) the timing of the $9.0 million cash payment to HCRx. Because such statements deal with future events and are based on Atara’s current expectations, they are subject to various risks and uncertainties and actual results, performance, or achievements of Atara could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks and uncertainties associated with our year-end the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; risks related to FDA’s review of tab-cel; our ability to access capital, and the sufficiency of Atara’s cash resources and access to additional capital on favorable terms or at all; and other risks and uncertainties affecting Atara, including those discussed in Atara’s filings with the Securities and Exchange Commission, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. Except as otherwise required by law, Atara disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events, or circumstances or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260223341002/en/
Investor and Media Relations
Amber Daugherty
Sr. Director, Strategy and Operations
adaugherty@atarabio.com
FAQ**
How will the renegotiated due date for the $9.0 million payment to HCRx affect Atara Biotherapeutics Inc. (ATRA)'s short-term liquidity and funding strategies?
Given the extended timeline until January 1, 2028, what specific steps will Atara Biotherapeutics Inc. (ATRA) take to address the concerns outlined in the recent CRL with the FDA?
What impact does the issuance of warrants for 400,000 shares have on the market perception of Atara Biotherapeutics Inc. (ATRA) and its future financing plans?
How does Atara Biotherapeutics Inc. (ATRA) plan to leverage its collaboration with Pierre Fabre and HCRx to maximize the potential of tabelecleucel for patients facing limited treatment options?
**MWN-AI FAQ is based on asking OpenAI questions about Atara Biotherapeutics Inc. (NASDAQ: ATRA).
NASDAQ: ATRA
ATRA Trading
38.17% G/L:
$6.715 Last:
1,253,418 Volume:
$5.71 Open:
